Bortezomib Recruiting Phase 1 Trials for Non-Hodgkin's Lymphoma (NHL) / Lymphoma, Hodgkins Treatment

IndicationsStatusPurposePhase
RecruitingTreatment1
clinicaltrials.gov IdentifierTitleDrugs
NCT02613598Dose Escalation Study to Determine the Maximum Tolerated Dose of the Combination of Ruxolitinib and Bortezomib in Patients With Relapsed or Refractory Lymphoma